MIAMI, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to...
With this initial capital infusion, combined with the exciting results from our initial eIND trials, we are anticipating an exciting remainder of 2020. We look forward to completing our audit and providing shareholders with further visibility into our continued clinical trials and product development plans in the near future.